Vimarsana
Biggest News Aggregation in the World

Solid Tumours News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Tumours. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Tumours Today - Breaking & Trending Today

BBCNEWS Breakfast July 5, 2024 - Vimarsana News

BBCNEWS Breakfast July 5, 2024

scotland and england with narrow wins in the six nations yesterday. it isa it is a cloudy but mild day and blush — it is a cloudy but mild day and blush day— it is a cloudy but mild day and blush day for many. wetter especially in western scotland. news of things— especially in western scotland. news of things turning colder this week. right _ of things turning colder this week. right here — of things turning colder this week. right here on breakfast. it's sunday, the 4th of february. our top story: the uk hasjoined the us in striking houthi targets in yemen for a third time....

Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer - Vimarsana News

Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer

1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly higher rates of grade 3 or higher adverse events compared to the placebo-chemoradiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Pembrolizumab has demonstrated efficacy in advanced cervical cancer, prompting an investigation into its potential

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC - Vimarsana News

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC

Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.

GSK : Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial - Form 6-K -December 18, 2023 at 06:38 am EST - Vimarsana News

GSK : Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial - Form 6-K -December 18, 2023 at 06:38 am EST

A1192x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER...

GSK : Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer - Form 6-K -October 30, 2023 at 07:13 am EDT - Vimarsana News

GSK : Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer - Form 6-K -October 30, 2023 at 07:13 am EDT

A6268r UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER...